EPIK-B4: A Phase II, multicenter, randomized, open-label, active-controlled study to assess the safety and efficacy of dapagliflozin + metformin XR versus metformin XR during treatment with alpelisib (BYL719) in combination with fulvestrant in participants with HR+, HER2-, advanced Breast Cancer with a PIK3CA mutation following progression on/after endocrine-based therapy
2022-11-27
عنوان الدراسة
EPIK-B4: A Phase II, multicenter, randomized, open-label, active-controlled study to assess the safety and efficacy of dapagliflozin + metformin XR versus metformin XR during treatment with alpelisib (BYL719) in combination with fulvestrant in participants with HR+, HER2-, advanced Breast Cancer with a PIK3CA mutation following progression on/after endocrine-based therapy
داعم الدراسة
Novartis Saudi Limited
دواء الدراسة
BYL719 / Alpelisib
رقم بروتوكول الدراسة
CBYL719C2202
حالة الدراسة
Completed
موقع الدراسة
King Fahad Specialist Hospital (Dammam),King Khalid University Hospital (Riyadh)
مرحلة الدراسة
2
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。